Treatment of progressive multiple sclerosis: Challenges and promising perspectives
- PMID: 29779852
- DOI: 10.1016/j.neurol.2018.01.370
Treatment of progressive multiple sclerosis: Challenges and promising perspectives
Abstract
Management of progressive multiple sclerosis (MS) is one of the main challenges of the new century. Based on our knowledge of pathophysiology, three therapeutic strategies are proposed: anti-inflammatory (ocrelizumab, siponimod…); remyelinating (opicinumab); and neuroprotective (high-dose biotin, ibudilast, simvastatin…). Nevertheless, despite recent promising positive clinical trials, new methodological approaches for therapeutic protocols with adaptable outcomes to assess progression are still needed.
Keywords: Design; Progressive multiple sclerosis; Symptomatic; Therapy; Treatment.
Copyright © 2018 Elsevier Masson SAS. All rights reserved.
Similar articles
-
Ibudilast for the treatment of multiple sclerosis.Expert Opin Investig Drugs. 2016 Oct;25(10):1231-7. doi: 10.1080/13543784.2016.1221924. Epub 2016 Aug 22. Expert Opin Investig Drugs. 2016. PMID: 27501293 Review.
-
Novel Drugs in a Pipeline for Progressive Multiple Sclerosis.J Clin Med. 2022 Jun 10;11(12):3342. doi: 10.3390/jcm11123342. J Clin Med. 2022. PMID: 35743410 Free PMC article. Review.
-
Progressive multiple sclerosis.Curr Opin Neurol. 2015 Jun;28(3):237-43. doi: 10.1097/WCO.0000000000000195. Curr Opin Neurol. 2015. PMID: 25887766 Free PMC article. Review.
-
Therapeutic Advances and Challenges in the Treatment of Progressive Multiple Sclerosis.Drugs. 2018 Oct;78(15):1549-1566. doi: 10.1007/s40265-018-0984-5. Drugs. 2018. PMID: 30255442 Review.
-
Progress in understanding the pathophysiology of multiple sclerosis.Rev Neurol (Paris). 2018 Jun;174(6):358-363. doi: 10.1016/j.neurol.2018.03.006. Epub 2018 Apr 19. Rev Neurol (Paris). 2018. PMID: 29680179 Review.
Cited by
-
Demyelination Lesions Do Not Correlate with Clinical Manifestations by Bordetella pertussis Toxin Concentrations.Life (Basel). 2022 Jun 27;12(7):962. doi: 10.3390/life12070962. Life (Basel). 2022. PMID: 35888052 Free PMC article.
-
BTK inhibition limits microglia-perpetuated CNS inflammation and promotes myelin repair.Acta Neuropathol. 2024 Apr 24;147(1):75. doi: 10.1007/s00401-024-02730-0. Acta Neuropathol. 2024. PMID: 38656399 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical